Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma

被引：209

作者：

Chen, Jiang ^{[1
]}

Jin, Renan ^{[1
]}

Zhao, Jie ^{[1
]}

Liu, Jinghua ^{[1
]}

Ying, Hanning ^{[1
]}

Yan, Han ^{[1
]}

Zhou, Senjun ^{[1
]}

Liang, Yuelong ^{[1
]}

Huang, Diyu ^{[1
]}

Liang, Xiao ^{[1
]}

Yu, Hong ^{[1
]}

Lin, Hui ^{[1
]}

Cai, Xiujun ^{[1
]}

机构：

[1] Zhejiang Univ, Dept Gen Surg, Sir Run Run Shaw Hosp, Hangzhou 310003, Zhejiang, Peoples R China

来源：

CANCER LETTERS | 2015年 / 367卷 / 01期

基金：

中国国家自然科学基金;

关键词：

Advanced hepatocellular carcinoma (HCC); Epithelial-mesenchymal transitions (EMT) and mesenchymal epithelial transitions (MET); Cancer stem cells (CSCs); Microenvironment; Acquired resistance; EPITHELIAL-MESENCHYMAL TRANSITION; HEDGEHOG SIGNALING PATHWAY; ALPHA-B-CRYSTALLIN; LIVER-CANCER CELLS; PHASE-III; PROMOTES METASTASIS; DEPENDENT MECHANISM; PLUS SORAFENIB; BREAST-CANCER; UP-REGULATION;

D O I：

10.1016/j.canlet.2015.06.019

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Sorafenib, an orally-available kinase inhibitor, is the only standard clinical treatment against advanced hepatocellular carcinoma. However, development of resistance to sorafenib has raised concern in recent years due to the high-level heterogeneity of individual response to sorafenib treatment. The resistance mechanism underlying the impaired sensitivity to sorafenib is still elusive though some researchers have made great efforts. Here, we provide a systemic insight into the potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma depending on abundant previous studies and reports. (C) 2015 Elsevier Ireland Ltd. All rights reserved.

引用

页码：1 / 11

页数：11

共 168 条

[11] Inflammation and Liver Cancer New Molecular Links
Berasain, C.
Castillo, J.
Perugorria, M. J.
Latasa, M. U.
Prieto, J.
Avila, M. A.
[J]. STEROID ENZYMES AND CANCER, 2009, 1155 : 206 - 221
[12] SLUG/SNAI2 and Tumor Necrosis Factor Generate Breast Cells With CD44+/CD24-Phenotype
Bhat-Nakshatri, Poornima
Appaiah, Hitesh
Ballas, Christopher
Pick-Franke, Patricia
Goulet, Robert, Jr.
Badve, Sunil
Srour, Edward F.
Nakshatri, Harikrishna
[J]. BMC CANCER, 2010, 10
[13] Cancer stem cells and EMT in carcinoma
Biddle, Adrian
Mackenzie, Ian C.
[J]. CANCER AND METASTASIS REVIEWS, 2012, 31 (1-2) : 285 - 293
[14] Bielecka Zofia F, 2014, Curr Signal Transduct Ther, V8, P218
[15] Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells
Blivet-Van Eggelpoel, Marie-Jose
Chettouh, Hamza
Fartoux, Laetitia
Aoudjehane, Lynda
Barbu, Veronique
Rey, Colette
Priam, Sabrina
Housset, Chantal
Rosmorduc, Olivier
Desbois-Mouthon, Christele
[J]. JOURNAL OF HEPATOLOGY, 2012, 57 (01) : 108 - 115
[16] Bolondi L, 2008, 2008 GASTR CANC S OR, P25
[17] Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
Bonnet, D
Dick, JE
[J]. NATURE MEDICINE, 1997, 3 (07) : 730 - 737
[18] Metronomic Capecitabine in Advanced Hepatocellular Carcinoma Patients: A Phase II Study
Brandi, Giovanni
de Rosa, Francesco
Agostini, Valentina
di Girolamo, Stefania
Andreone, Pietro
Bolondi, Luigi
Serra, Carla
Sama, Claudia
Golfieri, Rita
Gramenzi, Annagiulia
Cucchetti, Alessandro
Pinna, Antonio Daniele
Trevisani, Franco
Biasco, Guido
[J]. ONCOLOGIST, 2013, 18 (12) : 1256 - 1257
[19] Management of Hepatocellular Carcinoma: An Update
Bruix, Jordi
Sherman, Morris
[J]. HEPATOLOGY, 2011, 53 (03) : 1020 - 1022
[20] ERK1/2 Blockade Prevents Epithelial-Mesenchymal Transition in Lung Cancer Cells and Promotes Their Sensitivity to EGFR Inhibition
Buonato, Janine M.
Lazzara, Matthew J.
[J]. CANCER RESEARCH, 2014, 74 (01) : 309 - 319

← 1 2 3 4 5 6 7 8 9 10 →